ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 37465670

MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target.

Liu H and 3 others. Front Immunol, 2023. Cited by 51 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target. Papers, record 37465670. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37465670

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target.
PubMed
Journal
Front Immunol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
51
iCite
Relative citation ratio, by iCite
4.8
iCite
Revised in PubMed
2023-07-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu HHaoyu
2Wang ZZhicheng
3Zhou YYuntao
4Yang YYanming

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Myeloid-Derived Suppressor CellsMajor topic
Humans
Female
Immunotherapy
Immune System
Tumor Microenvironment

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References153

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133,456,560IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.Theranostics2021https://conductscience.org/library/papers/33456560PubMed
233,777,750The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.Front Oncol2021https://conductscience.org/library/papers/33777750PubMed
334,506,976Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.Acta Biomater2021https://conductscience.org/library/papers/34506976PubMed
431,110,935Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model.J Bone Oncol2019https://conductscience.org/library/papers/31110935PubMed
534,551,052DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.J Mater Chem B2021https://conductscience.org/library/papers/34551052PubMed
633,010,818Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.Mol Ther2021https://conductscience.org/library/papers/33010818PubMed
732,103,175Epigenetic therapy inhibits metastases by disrupting premetastatic niches.Nature2020https://conductscience.org/library/papers/32103175PubMed
832,213,179XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling.Cell Commun Signal2020https://conductscience.org/library/papers/32213179PubMed
932,554,250Chinese herbal medicine Baoyuan Jiedu decoction inhibits the accumulation of myeloid derived suppressor cells in pre-metastatic niche of lung via TGF-β/CCL9 pathway.Biomed Pharmacother2020https://conductscience.org/library/papers/32554250PubMed
1025,595,776Cancer-associated oxidoreductase ERO1-α drives the production of tumor-promoting myeloid-derived suppressor cells via oxidative protein folding.J Immunol2015https://conductscience.org/library/papers/25595776PubMed

1 to 10 of 153

See all 153 references

Cited by40

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.

PMIDTitleJournalYearIn PapersSource
42,960,449Emerging role of non‑coding RNAs in the progression of MASLD‑driven hepatocellular carcinoma (Review).Int J Mol Med2026https://conductscience.org/library/papers/42960449PubMed
42,953,055Epithelial-mesenchymal transition plasticity in breast cancer: regulatory mechanisms and therapeutic implications.Front Oncol2026https://conductscience.org/library/papers/42953055PubMed
42,720,907MYBL2 promotes malignant phenotypes and M2-like macrophage polarization through CCL2 in non-small cell lung cancer.Mol Cell Biochem2026https://conductscience.org/library/papers/42720907PubMed
42,608,394Harnessing macrophage signaling pathways and scalable engineering for next-generation immunotherapies.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42608394PubMed
42,558,596Cell competition within breast tumor microenvironment: emerging role of cancer stem cells and immune cells in tumor progression and therapeutic implications.Front Oncol2026https://conductscience.org/library/papers/42558596PubMed
42,454,051Wnt/β-Catenin-mTOR-autophagy crosstalk in breast cancer: context-dependent control of tumor progression, immune suppression, and therapeutic resistance.Front Immunol2026https://conductscience.org/library/papers/42454051PubMed
42,223,750Morpho-functional plasticity of tumour-associated macrophages: linking cell shape, ultrastructure, and immune regulation in cancer.Clin Exp Med2026https://conductscience.org/library/papers/42223750PubMed
42,143,109Pre-treatment of cabozantinib prior to hypofractionated radiotherapy increases immunomodulatory effects and tumor size reduction in a 4T1 breast cancer murine model.Sci Rep2026https://conductscience.org/library/papers/42143109PubMed
42,079,576B cell-mediated immune surveillance defines the favorable prognosis of occult breast cancer: a multi-omics study.Front Immunol2026https://conductscience.org/library/papers/42079576PubMed
42,035,063Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Mol Cancer2026https://conductscience.org/library/papers/42035063PubMed

1 to 10 of 40

See all 40 cited by

Genes38

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ADAM176,868PubTator's text mininghttps://conductscience.org/library/genes/6868NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ARG1383PubTator's text mininghttps://conductscience.org/library/genes/383NCBI Gene
CAMP820PubTator's text mininghttps://conductscience.org/library/genes/820NCBI Gene
CCR41,233PubTator's text mininghttps://conductscience.org/library/genes/1233NCBI Gene
CD14929PubTator's text mininghttps://conductscience.org/library/genes/929NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CSF1R1,436PubTator's text mininghttps://conductscience.org/library/genes/1436NCBI Gene
CSF21,437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
CSF31,440PubTator's text mininghttps://conductscience.org/library/genes/1440NCBI Gene

1 to 10 of 38

See all 38 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37465670

GET https://conductscience.org/api/papers/v1/37465670/references?page=2

API referenceFor AI assistants